Sam Martin
Net worth: 1 M $ as of 31/05/2026
Net worth: 1 M $ as of 31/05/2026
Sam Martin currently works at Celldex Therapeutics, Inc. as CFO, Secretary, Treasurer & Senior Vice President since 2009.
Formerly, Mr. Martin was Director-Finance & Corporate Compliance at Alseres Pharmaceuticals, Inc. and Audit Manager at Ernst & Young LLP.
Education includes an MBA from Boston University and an undergraduate degree from Skidmore College.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 10/04/2026 | 32,942 ( 0.04% ) | 1 M $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| CELLDEX THERAPEUTICS, INC. | Director of Finance/CFO | 01/04/2009 |
| Companies | Position | End |
|---|---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Corporate Officer/Principal | - |
| ALSERES PHARMACEUTICALS, INC. | Director of Finance/CFO | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Develops therapeutic and diagnostic products | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Commercial Services |
Boston University
Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Skidmore College
Skidmore College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes immunotherapy technologies for the treatment of cancer and other diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions